-- BioCancell Surges Most in Three Months on Cancer Trial Results
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-03-14T12:36:30Z
-- http://www.bloomberg.com/news/2012-03-14/biocancell-surges-most-in-three-months-on-cancer-trial-results.html
BioCancell Therapeutics Inc. (BICL)  jumped
the most in three months after the biotechnology company said
the results of ovarian cancer trials for its BC-819 treatment
support the expansion of the clinical trials.  The  shares advanced  as much as 8.8 percent, the biggest
gain since Dec. 11, to 0.84 shekel. It was at 0.82 shekel at
2:25 p.m. in  Tel Aviv , giving the Jerusalem-based company a
market value of 32.3 million shekels ($8.5 million).  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  